


REMARKS / ARGUMENTS

In response to the restriction requirement under 35 USC 121 and 372, Applicants elect the claims of Group II, claims 1-9, 11-16 and 19 drawn to a method of treatment. As single disclosed species of compound, Applicants elect midostaurin, also known as PKC412, which is disclosed on page 31 of the specification. Mastocytosis is elected as the particular disorder or condition.

Entry of this response is requested and an action on the merits is awaited.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "George R. Dohmann", written over a horizontal line.

George R. Dohmann
Attorney for Applicant
Reg. No. 33,593

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7824

Date: March 5, 2009